Preclinical,in vitroscreening for adverse drug reactions continues to present challenges in the field of drug development. In this issue ofCell Chemical Biology,Shah et al. (2017)employ a phenotypic screening strategy using a panel of human primary cells to define a signature response and an adverse outcome pathway for delayed type IV skin hypersensitivity.

中文翻译：

---

原代细胞表型筛选照亮了ADR和AOP

药物不良反应的临床前，体外筛选继续在药物开发领域提出挑战。在本期《细胞化学生物学》中，Shah等人。（2017）使用表型筛选策略，使用一组人类原代细胞来定义特征性应答和IV型皮肤超敏反应延迟的不良结果途径。